Iopamiro (Iopamidol)

Iopamidol provides radiographic contrast by delivering a high concentration of iodine atoms that absorb X‑ray photons, increasing attenuation of the beam in the administered area. This creates a difference in radiodensity between contrast‑filled vessels or spaces and surrounding tissues, allowing clearer imaging.

The dose of Iopamiro is individualized by the prescribing physician based on the specific imaging study, patient size, renal function, and the required level of contrast enhancement. The healthcare professional determines the appropriate volume and concentration for each procedure.

The safety of Iopamiro during pregnancy or lactation has not been definitively established. It should be used only if the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Iopamiro contains iopamidol, a non‑ionic, low‑osmolality iodinated contrast medium, which generally offers a lower incidence of discomfort and adverse reactions compared with older high‑osmolality agents. Its imaging performance is comparable to other low‑osmolality agents, while providing good vascular and tissue enhancement for angiography, CT and myelography.

Iopamiro should be stored at controlled room temperature, below 25 °C, in its original packaging to protect it from light and moisture. Do not freeze the product, and keep it out of reach of children. Verify the expiry date before use.

Iopamiro is administered by a qualified healthcare professional via intra‑arterial, intravenous or intrathecal injection, depending on the imaging procedure. The injection is typically performed using a sterile technique, and the volume and rate are adjusted according to the specific diagnostic requirement and patient factors.

The most serious risks include severe allergic or anaphylactoid reactions, renal toxicity especially in patients with pre‑existing kidney impairment, and rare neurologic events such as seizures. Prompt recognition and management of these reactions are essential, and patients should be monitored closely during and after administration.

Iopamiro should be avoided in patients with a known hypersensitivity to iopamidol or any iodinated contrast media, those with severe renal insufficiency where alternative imaging is possible, and individuals with a history of severe iodine‑related allergic reactions. The prescribing clinician must assess each patient’s risk before use.